News
NCNA
1.280
-3.03%
-0.040
Weekly Report: what happened at NCNA last week (0914-0918)?
Weekly Report · 4d ago
Weekly Report: what happened at NCNA last week (0907-0911)?
Weekly Report · 09/14 09:54
Weekly Report: what happened at NCNA last week (0831-0904)?
Weekly Report · 09/07 09:50
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 08/31 17:06
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 08/31 12:06
Weekly Report: what happened at NCNA last week (0824-0828)?
Weekly Report · 08/31 09:54
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 08/28 21:06
NuCana Has Been Granted European Patent Number EP3683225 Titled "NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS"
Benzinga · 08/28 20:00
Weekly Report: what happened at NCNA last week (0817-0821)?
Weekly Report · 08/24 09:55
Weekly Report: what happened at NCNA last week (0810-0814)?
Weekly Report · 08/17 09:56
NuCana Files Q2 2026 Results and Updates U.S. Registration Statements
TipRanks · 08/13 20:53
NuCana GAAP EPS of £0.00
Seeking Alpha · 08/13 20:35
NuCana Q2 2026
Benzinga · 08/13 20:16
Weekly Report: what happened at NCNA last week (0803-0807)?
Weekly Report · 08/10 09:52
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 08/07 21:05
Weekly Report: what happened at NCNA last week (0727-0731)?
Weekly Report · 08/03 09:52
Weekly Report: what happened at NCNA last week (0720-0724)?
Weekly Report · 07/27 09:55
Weekly Report: what happened at NCNA last week (0713-0717)?
Weekly Report · 07/20 09:52
Weekly Report: what happened at NCNA last week (0706-0710)?
Weekly Report · 07/13 09:54
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 07/10 17:05
More
Webull provides a variety of real-time NCNA stock news. You can receive the latest news about Nucana through multiple platforms. This information may help you make smarter investment decisions.
About NCNA
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.